Drug Profile
Research programme: cystic fibrosis transmembrane conductance regulator stimulants and inhibitors - University of California San Francisco/Vanda Pharmaceuticals
Alternative Names: Cystic fibrosis transmembrane conductance regulator activators - University of California San Francisco/Vanda Pharmaceuticals; Cystic fibrosis transmembrane conductance regulator inhibitors - University of California San Francisco/Vanda PharmaceuticalsLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator University of California at San Francisco
- Class Eye disorder therapies; Laxatives; Urologics
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors; Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Constipation; Diarrhoea; Dry eyes; Polycystic kidney disease
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Constipation in USA
- 28 Apr 2021 No recent reports of development identified for preclinical development in Diarrhoea in USA
- 28 Apr 2021 No recent reports of development identified for preclinical development in Dry-eyes in USA